Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 44,400 shares, a decrease of 15.9% from the January 31st total of 52,800 shares. Based on an average daily volume of 3,390,000 shares, the short-interest ratio is currently 0.0 days.

Insider Buying and Selling

In related news, CFO Gordon Dunn acquired 122,221 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, for a total transaction of $54,999.45. Following the completion of the acquisition, the chief financial officer now directly owns 151,077 shares in the company, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Anthony James Culverwell acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were purchased at an average price of $0.45 per share, with a total value of $45,000.00. Following the completion of the acquisition, the director now owns 100,317 shares of the company’s stock, valued at $45,142.65. This represents a 31,545.74 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 777,777 shares of company stock valued at $350,000. 3.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Quoin Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of QNRX. Apollon Wealth Management LLC bought a new position in shares of Quoin Pharmaceuticals in the fourth quarter worth about $52,000. Boothbay Fund Management LLC acquired a new stake in Quoin Pharmaceuticals in the fourth quarter valued at approximately $53,000. Renaissance Technologies LLC grew its stake in shares of Quoin Pharmaceuticals by 244.1% during the fourth quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock worth $87,000 after buying an additional 94,431 shares during the last quarter. Finally, Altium Capital Management LLC bought a new stake in shares of Quoin Pharmaceuticals during the fourth quarter worth $184,000. Institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Trading Up 10.2 %

Shares of QNRX traded up $0.03 during midday trading on Wednesday, reaching $0.33. The stock had a trading volume of 1,265,262 shares, compared to its average volume of 2,292,957. Quoin Pharmaceuticals has a one year low of $0.28 and a one year high of $1.74. The firm has a market cap of $1.64 million, a PE ratio of -0.08 and a beta of 1.72. The firm has a 50 day simple moving average of $0.44 and a 200-day simple moving average of $0.57.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.